Harrow has a large gap to its $54.81 analyst target and a cheap forward multiple, but it missed earnings in 3 of the last 4 quarters, is cash-burning with below-floor quality, and trades in a confirmed downtrend with 23% short interest.
Thesis pillars
- Large Gap To Analyst Target→Stable
- Cheap Forward Valuation→Stable
- Repeated Earnings Misses↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026, based on the 10-K filed Mar 2, 2026
Harrow, Inc. (HROW) Stock Analysis
Recovery setup · Inst Constrain edge
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Engine safety override at $28.75: Quality below floor (3.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 10.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 22%; Below-average business quality; Below long-term trend.
Harrow is a North American ophthalmic disease management company that markets a broad portfolio of FDA-approved branded eye-care pharmaceuticals, including IHEEZO, VEVYE, TRIESENCE, and biosimilars BYOOVIZ and OPUVIZ, alongside its ImprimisRx compounding pharmacy business... Read more
Sell if holding. Engine safety override at $28.75: Quality below floor (3.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 10.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 22%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 50. Score 5.3/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 4d<=7d. Suitability: speculative.
Recent developments
updated Nov 2, 2026Recent Developments — Harrow, Inc.
Latest news
- NEWS Harrow Launches HarrowRx Prescribing and Access Platform — fiscal.ai Nov 2, 2026 positive
- NEWS Harrow Announces Launch Of HarrowRx Pharmacy Platform For Prescribing All Its Branded Products Within Electronic Medical — benzinga Nov 2, 2026 positive
- NEWS Harrow to Report Third Quarter 2026 Financial Results on November 9, 2026 — fiscal.ai Oct 26, 2026
- NEWS BTIG Reiterates Buy on Harrow, Maintains $63 Price Target — benzinga Oct 7, 2026 positive
- NEWS Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach — benzinga Sep 25, 2026 neutral
Latest item Nov 2, 2026 · Generated 2026-11-05T11:49:10Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Unprofitable operations — net margin -13.5%. Quality floor flags this regardless of sector context.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $28.75: Quality below floor (3.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 10.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 22%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 50. Prior stop was $26.74. Score 5.3/10, moderate confidence.
Analyst target: $54.81 (+90.6% upside). Prior stop was $26.74. Stop-loss: $26.74.
Quality below floor (3.3 < 4.0).
Harrow, Inc. trades at a P/E of N/A (forward 10.4). TrendMatrix value score: 8.7/10. Verdict: Sell.
15 analysts rate HROW, with a consensus score of 4.3/5. 8 analysts publish price targets averaging $63.
What does Harrow, Inc. do?Harrow is a North American ophthalmic disease management company that markets a broad portfolio of FDA-approved branded...
Harrow is a North American ophthalmic disease management company that markets a broad portfolio of FDA-approved branded eye-care pharmaceuticals, including IHEEZO, VEVYE, TRIESENCE, and biosimilars BYOOVIZ and OPUVIZ, alongside its ImprimisRx compounding pharmacy business serving more than 10,000 U.S. eyecare prescribers and institutions. Harrow does not manufacture its own branded products, instead relying on third-party contract manufacturers across the U.S., France, Belgium, Spain, and Taiwan, and its revenue depends heavily on reimbursement from Medicare, Medicaid, and commercial payors.